DexCom (NASDAQ:DXCM) Director Mark Foletta Sells 4,000 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 4,000 shares of DexCom stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Down 2.6%

Shares of NASDAQ DXCM opened at $71.23 on Thursday. The stock has a market capitalization of $27.49 billion, a P/E ratio of 30.44, a P/E/G ratio of 1.14 and a beta of 1.45. The company has a 50-day moving average price of $66.75 and a 200-day moving average price of $67.82. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue was up 15.0% on a year-over-year basis. During the same period last year, the company earned $0.32 earnings per share. On average, equities research analysts forecast that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on DXCM shares. Benchmark initiated coverage on shares of DexCom in a report on Monday, May 11th. They issued a “buy” rating and a $77.00 price target on the stock. Barclays reissued an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Monday, May 18th. Finally, TD Cowen reissued a “buy” rating and issued a $95.00 price target (up from $75.00) on shares of DexCom in a research report on Wednesday, June 10th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $84.83.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Empowered Funds LLC increased its holdings in DexCom by 71.8% during the 1st quarter. Empowered Funds LLC now owns 17,623 shares of the medical device company’s stock worth $1,107,000 after acquiring an additional 7,367 shares during the period. Defilade Capital Management L.P. increased its holdings in DexCom by 120.0% during the 1st quarter. Defilade Capital Management L.P. now owns 538,762 shares of the medical device company’s stock worth $33,834,000 after acquiring an additional 293,881 shares during the period. Avidity Partners Management LP bought a new stake in DexCom during the 1st quarter worth approximately $5,652,000. Glenmede Trust Co. NA increased its holdings in DexCom by 36.7% during the 1st quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock worth $24,790,000 after acquiring an additional 105,928 shares during the period. Finally, Wellington Grp LLC increased its holdings in DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.